In other cancers, anticancer activity of checkpoint inhibitors has also been demonstrated as enhanced via the expression of various biomarkers, including programmed death ligand-1 (PD-L1), tumor mutational burden (TMB), tumor-infiltrating lymphocytes (TILs), and components of the tumor microenvironment (TME) [8,9,10]. This evidence concerns the gene CD274 and cancer.